BioXcel Therapeutics, Inc. (BTAI)

Over the past 52 weeks, BioXcel Therapeutics' stock has traded between $8.08 and $1.17. As of February 2, 2026, the share price was $1.59, a 67.70% decrease from February 3, 2025. Key events include Q2 2025 financial results with revenues of $0.12 million and a net loss of $19.2 million, positive market reaction to the SERENITY At-Home trial completion, H.C. Wainwright reiterating a Buy rating, Q3 2025 financial results showing a net loss of $30.9 million and doubts about the company's ability to continue as a going concern, the announcement and submission of an sNDA for IGALMI for at-home use, and the entry into milestone and retention bonus agreements with key executives.

Information on specific demand seasonality for BioXcel Therapeutics' products is not readily available. There is data indicating seasonal volatility in implied options for BTAI stock, with volatility tending to rise in March and decline in September. Significant seasonality in patient demand might not be a primary factor for pharmaceutical products addressing conditions like agitation, but this cannot be definitively confirmed.

BioXcel Therapeutics, Inc. is a biopharmaceutical company that uses artificial intelligence to develop medicines, focusing on neuroscience and immuno-oncology. They utilize existing drugs and machine learning to identify new therapeutic indications. Their products include IGALMI, a sublingual film approved for agitation, BXCL501, in Phase 3 trials for agitation and substance use disorders, and BXCL701, an oral immune activator that has completed Phase 1b/2a trials for various cancers.

BioXcel Therapeutics is headquartered in New Haven, Connecticut, and primarily operates within the United States, focusing on developing and commercializing medicines.

BioXcel Therapeutics' brand reputation has been influenced by positive clinical developments and financial challenges. The company has a consensus rating of "Hold" from analysts. Positive developments include promising data from the SERENITY At-Home trial and the use of AI for drug development. Challenges include potential clinical trial delays, unfavorable study results, regulatory approval obstacles, slow market uptake, and financial instability, as highlighted by Q3 2025 results and doubts about the company's ability to continue as a going concern.

BioXcel Therapeutics has 42 institutional owners and shareholders holding 2,468,937 shares. Major institutional owners include Millennium Management Llc, Vanguard Group Inc., Oaktree Capital Management Lp, FMR Llc, Geode Capital Management, Llc, XTX Topco Ltd, BlackRock, Inc., and State Street Corp. BioXcel Corporation is also a significant shareholder, and Oaktree Capital Management Lp holds primary leverage through the company's credit facility.